Walgreens Chair Pessina to boost stake after Sycamore seals takeover deal, FT reports
US will be hit by 'high tariffs' from other countries, China's Global Times warns
Swiss National Bank bought forex worth 1.2 billion francs in 2024
What to know about why Israel launched dozens of attacks across Gaza, raising fears of all-out war
Gabbard says Trump is committed to ensuring peace and security through 'realism and pragmatism'
Sport-Women's elite sports to generate more than $2.35 billion in 2025, says Deloitte
Steve Kerr committed to finding Stephen Curry a rest day, insists superstar guard is exhausted
Pelicans say Trey Murphy III will miss rest of the season with shoulder injuries
(Reuters) -AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing the impact of $82 million in milestones, and research and development expenses related to acquisitions.
The drugmaker expects annual adjusted profit per share in the range of $10.67 to $10.87, compared with its previous forecast of $10.71 to $10.91 per share, a regulatory filing showed.
Analysts were expecting $10.88 per share, according to estimates compiled by LSEG.
AbbVie also cut its forecast for third-quarter adjusted profit per share to $2.88 to $2.92 from $2.92 to $2.96 previously.
The company said it incurred $82 million in expenses during the quarter related to collaborations, licensing agreements and other asset acquisitions.
AbbVie is scheduled to report third-quarter results on Oct. 30.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
